Tag Archives: PulseSight Therapeutics

Pulsesight Pst 611 Phasei Dosingcompleted Dryamd Ga

BIOTECH

Dosing completed in the Phase I clinical trial of PulseSight Therapeutics’ PST-611 treatment for dry AMD/Geographic Atrophy (GA)
January 22, 2026

Paris, France, January 22, 2026 – PulseSight Therapeutics SAS, an ophthalmology clinical stage biotech company developing...

Read more
Pulsesight Series A Financing Pst 611 Dry Amd 2025 1

BIOTECH

PulseSight Therapeutics Announces First Close of its Series A Financing to Fund Clinical Development of PST-611 in dry AMD
February 13, 2025

PARIS, Feb. 13, 2025 (GLOBE NEWSWIRE) — PulseSight Therapeutics SAS, an ophthalmology biotech company developing...

Read more
Pulsesight Therapeutics Presents Pst 611 Ever Congress 2024

BIOTECH

PulseSight Therapeutics to Present Data on PST-611 at EVER Congress 2024
October 7, 2024

PARIS, Oct. 07, 2024 (GLOBE NEWSWIRE) — PulseSight Therapeutics SAS, an ophthalmology biotech company developing...

Read more
This site uses cookies to offer you a better browsing experience. By browsing this website, you agree to our use of cookies.
Accept